Results 201 to 210 of about 1,336,088 (341)

A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial) [PDF]

, 2016
Tomoki Kimura, Yasushi Nagata, Junko Eba, Shuichi Ozawa, Satoshi Ishikura, Taro Shibata, Yoshinori Ito, Masahiro Hiraoka, Yasumasa Nishimura, Radiation Oncology Study Group of the Japan Clinical Oncology Group   +9 more
openalex   +1 more source

European Code Against Cancer, 5th edition – hormone replacement therapy, other common medical therapies and cancer

Molecular Oncology, EarlyView.
The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations regarding the use of hormone replacement therapy (HRT), which is positioned as recommendation number 13 of the ECAC5.
Mangesh A. Thorat, Marc Arbyn, David Baldwin, Xavier Castells, Solveig Hofvind, Urska Ivanus, Carlo Senore, Esther Toes‐Zoutendijk, Carlijn van der Aalst, Carlos Canelo‐Aybar, Fiorella Karina Fernández‐Sáenz, Ariadna Feliu, Hajo Zeeb, Andre L. Carvalho, Erica D'Souza, David Ritchie, Carolina Espina, Iris Lansdorp‐Vogelaar, Andrea DeCensi   +18 more
wiley   +1 more source

Pharmacogenomics and Big Data in medical oncology: developments and challenges. [PDF]

Ther Adv Med Oncol
Marcu LG, Marcu DC.
europepmc   +1 more source

Department of Medical Oncology [PDF]

, 2010
吉田 睦浩, 山本 恵子, 濱 裕美, 竹本 朋代, 菓子井 達彦, 阿部 充伸, 須佐 充, 高木 昭佳   +7 more
core   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Addressing the Oncologist Shortage in Latin America: Insights From a Survey of Medical Oncology Fellowship Programs. [PDF]

JCO Glob Oncol
Zegarra-López M, Aranda-Gutierrez A, Muñoz Lozano JF, Villarreal-Garza C.   +3 more
europepmc   +1 more source

Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2024 [PDF]

Carolin Krekeler, Verena Turco, Annabel Helga Sophie Alig, Annalen Bleckmann, Michael Quante, C. Benedikt Westphalen, Kathrin Heinrich, Maryam Barsch   +7 more
openalex   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Workforce Trends Among Canadian Medical Oncologists and Medical Oncology Trainees over Two Decades. [PDF]

Curr Oncol
Fundytus A, Cook S, Yip SM, Loewen SK, Hao D.   +4 more
europepmc   +1 more source

Conference Report: European Society for Medical Oncology Congress 2022. [PDF]

Rare Tumors, 2023
Dogan S.
europepmc   +1 more source